A Phase 1/2 interventional study of CSB-001 Ophthalmic Solution 0.1% and Vehicle Control in Neurotrophic Keratitis, sponsored by Claris Biotherapeutics, Inc.. Completed at 48 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.
Sponsored by Claris Biotherapeutics, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Keratitis with a site in United States — 4 open to participants now, 4 under way, 1 of them phase 3. Keratitis · United States.
Among the 34 studies in Keratitis with a site in United States, this one is the 9th largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2021, is one of 3 in phase 1/2, and was the 27th registered.
108 studies on the registry are indexed under Keratitis; 19 are open to participants now.
Browse Keratitis studies →4 of the 34 studies in Keratitis with a site in United States are open now. Recruiting first, the newest first:
TearSolutions, Inc. · Sites in United States
Ages 18+
Krystal Biotech, Inc. · Sites in United States
Ages 18+
BRIM Biotechnology Inc. · Sites in United States
Ages 18+
Stanford University · Sites in United States, Brazil, India
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Keratitis studies recruiting now, 6 set no upper age limit and 1 stops at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 14 · Phase 3 5 · Phase 4 3
First in 1997; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 131 is above the median of 40 across 70 interventional studies indexed under Keratitis.
Median enrollment 60 across the 25 interventional studies, 60 across the 9 observational. Of the 26 that completed or were terminated, 13 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 34 have an industry lead sponsor. The 10 most frequent:
Claris Biotherapeutics, Inc. is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Claris Biotherapeutics, Inc. has 1 study filed under Keratitis — fewer than ten, so there is no comparison to draw.
2 of the studies in Keratitis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06999733Krystal Biotech, Inc.A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis | 2026-12 |
| NCT07568730TearSolutions, Inc.A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of Lacripep in Subjects With Neurotrophic Keratitis | 2027-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 34 studies in Keratitis with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will enroll subjects with stage 2 or 3 neurotrophic keratitis. Subjects will be randomized in a 1:1 ratio to the CSB-001 investigational treatment arm or vehicle control arm. All subjects will dose with the randomized treatment four times daily for 8 weeks (controlled treatment phase). During the controlled treatment phase, subjects will return to the clinic weekly from Day 0 to Week 8, and again at Week 10. Subjects randomized to the vehicle arm who are not healed will have the opportunity to participate in an open-label uncontrolled treatment phase.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: Other inclusion/exclusion criteria apply.
One drop CSB-001 four times daily for 8 weeks in the study eye
Biological: CSB-001 Ophthalmic Solution 0.1%
One drop matching vehicle four times daily for 8 weeks in the study eye
Biological: Vehicle Control
CSB-001: human recombinant dHGF (5-amino acid deleted hepatocyte growth factor)
Matching vehicle control without the drug substance
Efficacy as Assessed by Complete Corneal Healing
Percentage of subjects achieving complete corneal healing in study eye as assessed by the Central Reading Center (CRC). Complete corneal healing was defined as absence of corneal staining in the area of the defect/ulcer (i.e., 0 mm lesion) at Week 8 and the absence of corneal staining in the area of the defect/ulcer (i.e., 0 mm lesion) at Week 10.
Time frame: Week 8 through Week 10
Safety as Assessed by Adverse Event Reporting
Number of participants with ocular and systemic adverse events
Time frame: Screening (Day 0) through Week 10
| Milestone | CSB-001 Investigational Treatment Arm | Vehicle Control Arm |
|---|---|---|
| Started | 69 | 62 |
| Received csb-001 in uncontrolled investigational treatment arm | 0 | 25 |
| Completed | 62 | 56 |
| Not completed | 7 | 6 |
Percentage of subjects achieving complete corneal healing in study eye as assessed by the Central Reading Center (CRC). Complete corneal healing was defined as absence of corneal staining in the area of the defect/ulcer (i.e., 0 mm lesion) at Week 8 and the absence of corneal staining in the area of the defect/ulcer (i.e., 0 mm lesion) at Week 10.
| Participants | CSB-001 Investigational Treatment Arm | Vehicle Control Arm |
|---|---|---|
| Efficacy as Assessed by Complete Corneal Healing | 21 | 16 |
Number of participants with ocular and systemic adverse events
| Participants | CSB-001 Investigational Treatment Arm | Vehicle Control Arm |
|---|---|---|
| Any ocular TEAEs (study eye) | 32 | 35 |
| Any systemic TEAEs | 10 | 23 |
Collected over Controlled Treatment Phase: 10 weeks and Uncontrolled Treatment Phase: 10 weeks for a total of 20 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CSB-001 Investigational Treatment Arm | 2/69 (2.9%) | 8/69 (11.6%) | 18/69 (26.1%) |
| Vehicle Control Arm | 1/62 (1.6%) | 7/62 (11.3%) | 35/62 (56.5%) |
| CSB-001 Uncontrolled Investigational Treatment Arm | 0/25 (0%) | 1/25 (4%) | 5/25 (20%) |
| Event | CSB-001 Investigational Treatment Arm | Vehicle Control Arm | CSB-001 Uncontrolled Investigational Treatment Arm |
|---|---|---|---|
| AnemiaBlood and lymphatic system disorders | 0/69 | 0/62 | 1/25 |
| HyponatremiaMetabolism and nutrition disorders | 0/69 | 0/62 | 1/25 |
| Low hemoglobinInvestigations | 0/69 | 0/62 | 1/25 |
| Neurotrophic keratopathyEye disorders | 2/69 | 1/62 | 0/25 |
| CellulitisInfections and infestations | 0/69 | 1/62 | 0/25 |
| OsteomyelitisInfections and infestations | 0/69 | 1/62 | 0/25 |
| Pneumonia pseudomonalInfections and infestations | 0/69 | 1/62 | 0/25 |
| FallInjury, poisoning and procedural complications | 1/69 | 1/62 | 0/25 |
| Ankle fractureInjury, poisoning and procedural complications | 0/69 | 1/62 | 0/25 |
| Haemoglobin decreasedInvestigations | 0/69 | 1/62 | 0/25 |
| Event | CSB-001 Investigational Treatment Arm | Vehicle Control Arm | CSB-001 Uncontrolled Investigational Treatment Arm |
|---|---|---|---|
| Visual acuity reducedEye disorders | 3/69 | 4/62 | 3/25 |
| Neurotrophic keratopathyEye disorders | 7/69 | 3/62 | 1/25 |
| Eye irritationEye disorders | 2/69 | 5/62 | 0/25 |
| Corneal oedemaEye disorders | 0/69 | 5/62 | 0/25 |
| Instillation site painGeneral disorders | 1/69 | 5/62 | 1/25 |
| COVID-19Infections and infestations | 1/69 | 5/62 | 0/25 |
| Eye painEye disorders | 0/69 | 0/62 | 2/25 |
| Ocular hyperaemiaEye disorders | 3/69 | 4/62 | 0/25 |
| Conjunctival hyperaemiaEye disorders | 1/69 | 4/62 | 1/25 |
Intent-to-Treat defined as all subjects who were randomized and had post-baseline efficacy data.
| Age, Continuous(years) | CSB-001 Investigational Treatment Arm | Vehicle Control Arm | Total |
|---|---|---|---|
| Mean | 64.3 ± 18.13 | 68.1 ± 14.72 | 66.1 ± 16.62 |
| Age, Continuous(years) | CSB-001 Investigational Treatment Arm | Vehicle Control Arm | Total |
|---|---|---|---|
| Median | 66.0 (25 to 94) | 72.0 (22 to 89) | 70.0 (22 to 94) |
| Age, Customized(Participants) | CSB-001 Investigational Treatment Arm | Vehicle Control Arm | Total |
|---|---|---|---|
| Age group, n (%) — < 60 | 23 | 13 | 36 |
| Age group, n (%) — ≥ 60 | 44 | 49 | 93 |
| Sex: Female, Male(Participants) | CSB-001 Investigational Treatment Arm | Vehicle Control Arm | Total |
|---|---|---|---|
| Female | 38 | 34 | 72 |
| Male | 29 | 28 | 57 |
| Ethnicity (NIH/OMB)(Participants) | CSB-001 Investigational Treatment Arm | Vehicle Control Arm | Total |
|---|---|---|---|
| Hispanic or Latino | 11 | 13 | 24 |
| Not Hispanic or Latino | 56 | 49 | 105 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | CSB-001 Investigational Treatment Arm | Vehicle Control Arm | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 2 |
| Asian | 2 | 2 | 4 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 2 |
| Black or African American | 3 | 2 | 5 |
| White | 56 | 55 | 111 |
| More than one race | 2 | 1 | 3 |
| Unknown or Not Reported | 2 | 0 | 2 |
| Current Neurotrophic Keratitis (NK) Stage(Participants) | CSB-001 Investigational Treatment Arm | Vehicle Control Arm | Total |
|---|---|---|---|
| Stage 2 | 49 | 41 | 90 |
| Stage 3 | 18 | 21 | 39 |
| Time since Current NK stage Diagnosis(months) | CSB-001 Investigational Treatment Arm | Vehicle Control Arm | Total |
|---|---|---|---|
| Median | 2.50 (0.0 to 209.0) | 2.45 (0.0 to 306.2) | 2.50 (0.0 to 306.2) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2021 to primary completion in May 2024, 32 months.
Results were first posted in May 2026, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CSB-001
Claris Biotherapeutics, Inc.